Core Insights - The National Healthcare Security Administration (NHSA) has included 114 new drugs in the national basic medical insurance catalog, covering various fields such as oncology, anti-infection, and chronic diseases [1][3] - The newly added drugs include significant innovations like GLP-1 diabetes medication Tirzepatide and long-acting growth hormone product Ipexi [1][3] - A new commercial health insurance innovation drug catalog has been introduced, featuring 19 products, including CAR-T therapies and new Alzheimer's drugs, aimed at addressing the payment challenges of high-priced innovative drugs [3][4] Summary by Category New Drug Additions - The updated medical insurance catalog includes drugs for chronic diseases, such as Tirzepatide for diabetes and Inclisiran for cholesterol reduction [1][2] - Other notable inclusions are Dupilumab for atopic dermatitis and the flu drug Masitinib [1] Pricing and Discounts - Although the NHSA did not disclose average price reductions, it is speculated that the discount rates may align with previous years' reductions of 50%-60% [3] - The long-acting growth hormone Ipexi is reported to have a price of approximately 850 yuan per injection, reflecting a nearly 50% reduction [3] Commercial Health Insurance Catalog - The commercial health insurance catalog aims to resolve the payment difficulties associated with high-priced innovative drugs, with 19 products included, of which 5 are CAR-T therapies [3][4] - The discount range for these products is between 15%-50%, slightly higher than the previously expected 30% [3][4] Market Dynamics and Implications - The inclusion of CAR-T therapies in the commercial insurance catalog marks a significant development, providing a national reimbursement pathway for these high-cost treatments [4][5] - The commercial insurance catalog's products benefit from a "three exclusions" policy, which allows for more favorable pricing and reimbursement conditions [4][6] Future Outlook - The introduction of the commercial insurance catalog is seen as a first step, with the focus now shifting to its implementation and integration with existing health insurance products [8][10] - The "Hui Min Bao" insurance products are expected to play a crucial role in accommodating the new catalog, with many products already providing coverage for CAR-T therapies [9][10] - The NHSA emphasizes a collaborative approach between basic medical insurance and commercial insurance, aiming for a complementary rather than competitive relationship [11]

Group 1 - The first version of the commercial insurance innovative drug directory will be officially released on the first weekend of December [1] - From October 30 to November 3, the National Healthcare Security Administration organized negotiations for the 2025 National Basic Medical Insurance Drug Directory and price negotiations for the commercial insurance innovative drug directory, with 120 domestic and foreign companies participating [2] - The new basic medical insurance drug directory and the first version of the commercial insurance innovative drug directory are expected to be released online and offline in Guangzhou, with implementation starting on January 1 of the following year [2] Group 2 - The establishment of the commercial insurance innovative drug directory has become a focal point in the industry, aimed at improving the accessibility of innovative drugs [3] - In 2023, the payment structure for innovative drugs in China shows that personal payments account for 49%, basic medical insurance for 44%, and commercial health insurance for only 7% [3]